Notice of updates

We’ve updated our Financial Services Guide (FSG), effective 18 November 2025. By continuing to use our services after this date, you accept the revised terms.

Read FSG

icon
HALO logo
halo search icon
Racura Oncology Ltd

AU$3.13

Price Change Indicator
0.20 (6.83%)
Racura Oncology Ltd
RAC · ASX

Racura Oncology Ltd

Start Trading RAC for Free

AU$3.13

Price Arrow0.20 (6.83%)
17/04/2026 04:10:01 PM
All-CompaniesAll-ConsensusGROWTH AUSHALO Consensus ValueHALO MomentumHALO Ords
Consensus Score
Lock Icon/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

Racura Oncology Ltd Overview

RAC Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

HALO Model

Mqv

Very Weak

Garp

Very Weak

Mqv Small

Neutral

Valuation

Value

Lock Icon

Consensus

Lock Icon

Momentum

Price

Strong

Earnings

Strong

Growth

Earnings

Very Weak

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

About RAC

icon
icon

Telephone

61.2.8051.3043

icon

Address

Level 36, Gateway, 1 Macquarie Place, Sydney, New South Wales (NSW) 2000

Description

Racura Oncology Ltd. is a Phase 3 clinical biopharmaceutical company with a dedicated mission to be at the heart of cancer care. Its asset, RCDS1 (E,E-bisantrene), is a small molecule anticancer agent that primarily functions via G4-DNA & RNA binding, resulting to potent inhibition of the important cancer growth regulator MYC. RCDS1 has demonstrated therapeutic activity in cancer patients with a well characterised safety profile. The company is advancing a proprietary formulation of RCDS1 (RC220) to address the high unmet needs of patients across multiple oncology indications, with Phase 3 clinical programs in acute myeloid leukaemia (AML), Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program in combination with the anthracycline doxorubicin, where the company aim to deliver both cardioprotection and enhanced anticancer activity for solid tumour patients. The company was founded on February 15, 2011 and is headquartered in Sydney, Australia.

RAC Price Chart

Key Stats

Market Cap

AU$535.35M

PE

0.00

EV/EBITDA

N/A

Dividends Overview

DIV Yield

0%

Franking

0%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.93 - 4.9

Trade Value (12mth)

AU$181,364.00

1 week

10.6%

1 month

7.93%

YTD

9.06%

1 year

238.38%

All time high

4.90

Key Fundamentals

EPS 3 yr Growth

-62.00%

EBITDA Margin

0.00%

Operating Cashflow

-$5m

Free Cash Flow Return

-26.70%

ROIC

-27.90%

Interest Coverage

0.00

Quick Ratio

10.30

Other Data

Shares Outstanding (Fully Diluted)

174m

HALO Sector

Healthcare

Next Company Report Date

01-Sep-26

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

RAC Announcements

Latest Announcements

DateAnnouncements
12 March 26
05 March 26
04 March 26
03 March 26
27 February 26

RAC Fundamentals

Per Share Records

Historical data

Forecast data

AUD2021202220232024202320242025202620272028
Per Share, Growth & Valuations
EPS (Basic)
 $locklocklocklock-0.06-0.08-0.03locklocklock
EPS (Fully Diluted)
 $locklocklocklock-0.06-0.08-0.03locklocklock
Growth
 %locklocklocklock15.6-36.166.9locklocklock
PE
 XlocklocklocklockN/AN/AN/Alocklocklock
EV/EBITDA
 XlocklocklocklockN/AN/AN/Alocklocklock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

0%

DPSg

N/A

Quality Yield

lock

Falling Divs over next 2

lock

Values and Recommendations

Key Stats

Consensus Score

lock

Recommendation

lock

EPS 1 month Change

lock

Quality Yield

lock

Falling Divs over next 2

lock

HALO Consensus Score

PEG Ratio

Consensus EPS Revisions

Short Selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

0

7 Day Change

0.00%

1 Month Change

0.00%

3 Months Change

0.00%

Dividend
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

RAC Shortsell

Related Companies

CSL - ASX
CSL Limited

CSL · ASX

CSL Limited

AU$137.13

Price Change Indicator

-0.42 (-0.305%)

RMD - ASX
ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh

RMD · ASX

ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh

AU$31.52

Price Change Indicator

-0.50 (-1.562%)

SIG - ASX
Sigma Healthcare Ltd

SIG · ASX

Sigma Healthcare Ltd

AU$2.80

Price Change Indicator

0.06 (2.19%)

Want to learn more?Frequently asked questions.
What is the current share price of Racura Oncology Ltd (RAC:ASX)?
Halo FAQ
The current share price of Racura Oncology Ltd (RAC:ASX) is AUD$3.13.
What is the 52-week high share price for Racura Oncology Ltd (RAC:ASX)?
Halo FAQ
The 52-week high share price for Racura Oncology Ltd (RAC:ASX) is AUD$4.90.
What is the 52-week low share price for Racura Oncology Ltd (RAC:ASX)?
Halo FAQ
The 52-week low share price for Racura Oncology Ltd (RAC:ASX) is AUD$0.93.
What is the dividend yield for Racura Oncology Ltd (RAC:ASX)?
Halo FAQ
Racura Oncology Ltd (RAC:ASX) does not pay a dividend.
What was Racura Oncology Ltd (RAC:ASX) last dividend payment?
Halo FAQ
Racura Oncology Ltd (RAC:ASX) does not pay a dividend.
What is the franking level for Racura Oncology Ltd (RAC:ASX)?
Halo FAQ
Racura Oncology Ltd (RAC:ASX) has a franking level of 0.00%.
In which sector is Racura Oncology Ltd (RAC:ASX) classified?
Halo FAQ
Racura Oncology Ltd (RAC:ASX) is classified in the Healthcare.

See beyond the curve.

One solution for research, investing and portfolio management.
Start FREE Trial